Johns Hopkins Antibiotic (ABX) GuideBrand Names

Anthrax vaccine

Kathryn Dzintars, PharmD, BCPS, Paul A. Pham, Pharm.D.

VACCINE TYPE

Anthrax vaccine (AVA, BIOTHRAX), killed vaccine made from the cell-free filtrate of nonencapsulated, attenuated strain of B. anthracis culture that contains no dead or live bacteria (note: a live attenuated vaccine was manufactured in the former USSR, but no longer available).

INDICATIONS

ACIP RECOMMENDATIONS

  • Routine vaccination with anthrax vaccine indications for persons engaged in:
  1. work involving production quantities or concentrations of B. anthracis cultures.
  2. activities with a high potential for anthrax aerosol production
  • Routine anthrax vaccine NOT recommended:
    • Laboratory personnel using standard Biosafety Level 2 practices in the routine processing of clinical samples are not at increased risk for exposure to B. anthracis spores.
  • Veterinarians in the U.S. not recommended because of the low incidence of animal cases.
    • Vaccination may be considered in high-risk persons handling potentially infected animals in areas with a high incidence of anthrax cases.
  • For bioterrorism preparedness (e.g., first responders, federal responders, medical practitioners, and private citizens).
    • The Working Group on Civilian Biodefense does recommend vaccination of exposed persons following a biological attack in conjunction with abx administration for 60 days following exposure.
  • ACIP recommends that if antimicrobial prophylaxis is administered in combination with post-exposure vaccination, it is prudent to continue antibiotics until 7-14 days after the third vaccine dose.

OTHER INFORMATION

  • Post-exposure prophylaxis: AVA given as a sole agent was not effective in one primate study. AVA was effective if abx with activity against anthrax was given concurrently. The duration of post-exposure antimicrobial prophylaxis should be 60 days if used alone for PEP of unvaccinated exposed persons.
  • Department of Defense has mandated some U.S. military active- and reserve-duty personnel receive pre-exposure (vaccine) prophylaxis as an adjunct to prolonged post-exposure antibiotic prophylaxis.
  • Pre-exposure vaccination of some persons deemed to be in high-risk groups should also be considered.

FORMS

brand name

preparation

manufacturer

route

form

dosage^

cost*

BioThrax

Anthrax Vaccine Adsorbed

Bioport Corp, Lansing, Michigan.

SQ

Vial

10 doses/ vial

$900 per vial

*Prices represent cost per unit specified, are representative of "Average Wholesale Price" (AWP).
^Dosage is indicated in mg unless otherwise noted.

PATHOGEN DIRECTED PROTECTION

DOSE/ADMINISTRATION

Adult PRIMARY SERIES

Dose (pre-exposure prophylaxis): 0.5 ml IM x 5 doses at 0 and 4 wks followed by injections at 6, 12 and 18 mos.

Adult BOOSTER

Revaccination: yearly booster dose (0.5ml) required to maintain immunity.

Pediatric PRIMARY SERIES

Not approved or studied in children (< 18 yrs old). Regimen of 3 doses at 0, 2 and 4 weeks after exposure (along with antimicrobial prophylaxis) available under IND protocol (#10061) if public health authorities determine an exposure event has occurred and use if justified.

Pediatric BOOSTER

See above.

Pediatric Dosing Author: George K Siberry, MD, MPH

ADVERSE DRUG REACTIONS

GENERAL

  • No long-term sequelae reported
  • Generally well tolerated

COMMON

  • Injection site nodule: most frequently reported local reaction and more common in women for unexplained reasons (60% vs 30% in men).
  • About 4% develop extensive erythema and swelling that may extend to the antecubital fossa --often misdiagnosed as bacterial cellulitis.

OCCASIONAL

  • Headache (0.4%)
  • Myalgia or arthralgia
  • Headache
  • Fatigue

RARE

  • Anaphylaxis

VACCINE/DRUG INTERACTIONS

  • No known drug interaction

CONTRAINDICATIONS

  • History of an anaphylactic reaction to the vaccine. Previous anthrax infection (re: more severe adverse events among recipients with a vaccine history of anthrax).

IMMUNE RESPONSE

Relationship between immunity and quantitative antibody levels has not been evaluated. Onset of protection: antibody titer increased 3-4x approximately 7d after the second dose (3-4 wks from first dose), however clear minimum therapeutic antibody response has not been established, but appears to be sufficient to prevent development of disease once antibiotics were discontinued. An estimated 83% of human vaccinees develop a vaccine-induced immune response after two doses of the vaccine and >95% develop a four fold rise in antibody titer after three doses.

CLINICAL EFFICACY

  • Effective in a placebo-controlled human trial against cutaneous anthrax. Primate models showed that antibiotic prevented inhalation anthrax, but were not protected from re-challenge.
  • However, all animals given vaccine PLUS antibiotic were protected with re-challenge [4].

OTHER INFORMATION

  • Vaccine indicated only for risk of inhalation anthrax, but prevents cutaneous anthrax as well.
  • Post-exposure prophylaxis with antmicrobials is still the preferred management.
  • The risk for persons who come in contact in the workplace with imported animal hides, furs, bone meal, wool, animal hair, or bristles has been reduced by changes in industry standards and import restrictions.
    • Routine preexposure vaccination is recommended only for persons in this group for whom these standards and restrictions are insufficient to prevent exposure to anthrax spores.
  • Safety in Pregnancy: Category D. Earlier unpublished study of infants born to women in the U.S. military service worldwide in 1998 and 1999 suggest that the vaccine may be linked with an increase in the number of birth defects. However, a published study found no effect on pregnancy or adverse birth outcomes in a cohort involving 4092 women [6].
  • Potentially exposed persons should be observed for signs of febrile illness.

Basis for recommendation

  1. Advisory Committee on Immunization Practices: Use of anthrax vaccine in the United States. MMWR Recomm Rep 49:1, 2000  [PMID:11145529]

    Comment: ACIP recommendations

  2. Centers for Disease Control and Prevention (CDC): Use of anthrax vaccine in response to terrorism: supplemental recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 51:1024, 2002  [PMID:12458919]

    Comment: ACIP recommendations

  3. Wright JG et al: Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 59:1, 2010  [PMID:20651644]

    Comment: Current CDC/ACIP recommendations.

References

  1. Friedlander AM et al: Postexposure prophylaxis against experimental inhalation anthrax. J Infect Dis 167:1239, 1993  [PMID:8486963]
  2. Meaney-Delman D et al: Special considerations for prophylaxis for and treatment of anthrax in pregnant and postpartum women. Emerg Infect Dis 20:, 2014  [PMID:24457117]
  3. Wiesen AR, Littell CT: Relationship between prepregnancy anthrax vaccination and pregnancy and birth outcomes among US Army women. JAMA 287:1556, 2002  [PMID:11911758]
Anthrax vaccine is a sample topic from the Johns Hopkins Antibiotic (ABX) Guide.

To view other topics, please or purchase a subscription.

Johns Hopkins Guides provide diagnosis, management, and treatment guidance for infectious diseases, diabetes, and psychiatric conditions. Learn more.

Last updated: August 3, 2016